CN116751164B - 蛋白酶抑制剂、其制备和用途 - Google Patents

蛋白酶抑制剂、其制备和用途

Info

Publication number
CN116751164B
CN116751164B CN202310629540.5A CN202310629540A CN116751164B CN 116751164 B CN116751164 B CN 116751164B CN 202310629540 A CN202310629540 A CN 202310629540A CN 116751164 B CN116751164 B CN 116751164B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
compounds
coronavirus
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310629540.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN116751164A (zh
Inventor
于洪涛
胡奇
黄晶
王廷亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xihu Pharmaceutical Hangzhou Co ltd
Original Assignee
Xihu Pharmaceutical Hangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xihu Pharmaceutical Hangzhou Co ltd filed Critical Xihu Pharmaceutical Hangzhou Co ltd
Publication of CN116751164A publication Critical patent/CN116751164A/zh
Application granted granted Critical
Publication of CN116751164B publication Critical patent/CN116751164B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202310629540.5A 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途 Active CN116751164B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2021/071256 WO2022150962A1 (en) 2021-01-12 2021-01-12 Protease inhibitors, preparation, and uses thereof
CNPCT/CN2021/071256 2021-01-12
CN202110336891.8A CN113072497B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110336891.8A Division CN113072497B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Publications (2)

Publication Number Publication Date
CN116751164A CN116751164A (zh) 2023-09-15
CN116751164B true CN116751164B (zh) 2026-03-13

Family

ID=75277880

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310629540.5A Active CN116751164B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途
CN202110336891.8A Active CN113072497B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110336891.8A Active CN113072497B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Country Status (5)

Country Link
US (1) US11958830B2 (https=)
EP (1) EP4026830A1 (https=)
JP (1) JP7611045B2 (https=)
CN (2) CN116751164B (https=)
WO (1) WO2022150962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2024178473A (ja) * 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN118076593A (zh) 2021-09-07 2024-05-24 上海齐鲁制药研究中心有限公司 3CLpro蛋白酶抑制剂
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
WO2024081351A1 (en) 2022-10-14 2024-04-18 Abbvie Inc. Pyrrolidine main protease inhibitors as antiviral agents
WO2024124287A1 (en) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Compounds for treating viral infection
WO2024183629A1 (zh) * 2023-03-03 2024-09-12 齐鲁动物保健品有限公司 3CLpro蛋白酶抑制剂在制备治疗猫冠状病毒疾病药物中的用途
EP4695230A1 (en) * 2023-04-11 2026-02-18 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Protease inhibitors and uses thereof
EP4722196A1 (en) 2023-05-31 2026-04-08 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Crystal of viral protease inhibitor and use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732446B1 (en) * 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
CN104334532A (zh) * 2012-01-30 2015-02-04 霍夫曼-拉罗奇有限公司 异喹啉和二氮杂萘衍生物
WO2016036638A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2020065613A1 (en) * 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US6335350B1 (en) 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
IL143262A0 (en) * 1998-12-09 2002-04-21 American Home Prod Thiourea inhibitors of herpes viruses
CZ20012060A3 (cs) * 1998-12-09 2001-11-14 American Home Products Corporation Thiomočovinové sloučeniny obsahující acetamid a substituovaný acetamid jako inhibitory herpes virů
TW200306159A (en) 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7067529B2 (en) 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
CN100475209C (zh) * 2003-07-15 2009-04-08 阿利健制药有限公司 抗冠状病毒剂
EP1845988A2 (en) * 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
WO2008088744A1 (en) * 2007-01-17 2008-07-24 Merck & Co., Inc. Decahydroquinoline analogs as cb2 receptor modulators
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
EP2576514A1 (en) 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
IN2014MN01982A (https=) 2012-04-25 2015-07-10 Raqualia Pharma Inc
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR101715090B1 (ko) * 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
KR20150027922A (ko) * 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
JP6936820B2 (ja) 2016-06-30 2021-09-22 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのアザデカリン誘導体
CN107674029A (zh) 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11247970B2 (en) 2017-03-22 2022-02-15 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
EP3829719B1 (en) 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
EP3982954A4 (en) * 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732446B1 (en) * 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN104334532A (zh) * 2012-01-30 2015-02-04 霍夫曼-拉罗奇有限公司 异喹啉和二氮杂萘衍生物
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2016036638A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2020065613A1 (en) * 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN检索报告;NIH Chemical Genomics Centerdeng 等;《数据库 REGISTRY（在线）》;20200618;第1-40页 *

Also Published As

Publication number Publication date
JP2022108241A (ja) 2022-07-25
JP7611045B2 (ja) 2025-01-09
CN113072497A (zh) 2021-07-06
CN116751164A (zh) 2023-09-15
US20220227731A1 (en) 2022-07-21
US11958830B2 (en) 2024-04-16
CN113072497B (zh) 2023-04-14
WO2022150962A1 (en) 2022-07-21
EP4026830A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
CN116751164B (zh) 蛋白酶抑制剂、其制备和用途
CN114507221B (zh) 一种三嗪类化合物及其在制备抗病毒药物上的用途
WO2023173708A1 (zh) 三嗪类化合物或其可药用盐、异构体、药物组合物和用途
MD3953330T2 (ro) Compuși care conțin nitril utili în calitate de agenți antivirali pentru tratamentul infecției cu coronavirus
CN114790198B (zh) 一种三嗪类化合物及其制备方法和应用
ES2589459T3 (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevención de una enfermedad viral
CA2948080A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
WO2014165128A2 (en) Hepatitis b antiviral agents
CA2952541A1 (en) Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
AU2012358332A1 (en) Hepatitis B antiviral agents
CN110105348A (zh) 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
CN102526087B (zh) 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
WO2023283831A1 (zh) 病毒主蛋白酶抑制剂及其制备方法和用途
CN115160301B (zh) 一种山荷叶素衍生物、其制备方法及用途
JP2018501268A (ja) チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途
CA3174790A1 (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
CN113773259A (zh) 病毒主蛋白酶抑制剂及其制备方法和用途
HK40050067A (en) Protease inhibitors, preparation, and uses thereof
HK40050067B (en) Protease inhibitors, preparation, and uses thereof
HK40077416A (en) Protease inhibitors, preparation, and uses thereof
TW202031666A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-噻唑并[5,4-c]吡啶脲活性劑
WO2024089159A1 (en) Main protease inhibitors
CN118176202A (zh) 一种含氰基取代的多肽类化合物的晶型及其制备方法
WO2024212101A1 (en) Protease inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant